Literature DB >> 6181177

Enhancement of interferon-mediated protein kinase in mouse and human plasma in response to treatment with polyadenylic-polyuridylic acid (poly A:poly U).

A G Hovanessian, Y Rivière, L Montagnier, M Michelson, J Lacour, F Lacour.   

Abstract

Interferon-treated mouse and human cells show enhanced levels of kinase activity manifested by the phosphorylation of endogenous 67,000 (p67K kinase) and 72,000 (p72K kinase) molecular weight proteins, respectively. Both the p67K kinase and the p72K activities are detectable in mouse and human plasma. We have previously shown that the p67K kinase in the plasma of mice may serve as a marker for the presence and action of interferon. Here we show that these kinase activities are enhanced in mice and in patients treated with polyadenylic-polyuridylic acid (Poly A:Poly U) at doses (0.4-0.6 mg/kg body weight) which do not lead to detectable amount of circulating interferon. Mice injected with higher doses of Poly A:Poly U (2-10 mg/kg body weight) show detectable levels of circulating interferon in addition to enhanced levels of p67K kinase in their plasma. Interferon produced under these conditions is acid stable.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181177     DOI: 10.1089/jir.1982.2.209

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  3 in total

1.  Involvement of gamma interferon in antibody enhancement by adjuvants.

Authors:  M J Odean; C M Frane; M Van derVieren; M A Tomai; A G Johnson
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

2.  Abrogation of the tumor promoting effect of allogeneic blood transfusion by polyadenylic-polyuridylic acid (poly A-poly U).

Authors:  S K Singh; R L Marquet; D L Westbroek; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A:U against solid Meth A tumors in mice.

Authors:  N Bloksma; F M Hofhuis
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.